Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
about
PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas)Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanomaCell Adhesion Molecules and Ubiquitination-Functions and SignificanceTargeting CXCR1/CXCR2 receptor antagonism in malignant melanomaEvaluation of CD146 as Target for Radioimmunotherapy against OsteosarcomaProteomes and signalling pathways of antler stem cellsA novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis.CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progressionSequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.Angiogenesis and progression in human melanoma.Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis developmentDifferential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma CellsChanges in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factorCD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancerThe metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM.Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancersAngiogenesis in melanoma.NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.ImmunoPET Imaging of CD146 Expression in Malignant Brain TumorsThe good and the bad of chemokines/chemokine receptors in melanoma.Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.CXCL8 and its cognate receptors in melanoma progression and metastasis.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Why is melanoma so metastatic?Angiogenesis in melanoma: an update with a focus on current targeted therapies.The multifaceted role of CD146/MCAM in the promotion of melanoma progression.Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients.Extracellular protonation modulates cell-cell interaction mechanics and tissue invasion in human melanoma cells.CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms.CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.Characterising the phenotypic evolution of circulating tumour cells during treatment.
P2860
Q21090021-A1EFC91C-76FF-4BEF-AE95-518A07C6494FQ24656407-B896CF2C-BD43-408E-AF3C-5CF0D7BD1ED4Q26771983-7E49964F-F249-4B4B-A5BD-0B5145FDC22AQ28276026-2738C68D-5545-4606-9A04-B73CA720347BQ28552916-AA586788-1B0A-4DA5-95DA-28D7A1726BC9Q28732723-411F286F-51E0-4496-BADE-41EB4BF19CBAQ30501230-4FECD1AD-3262-4F4E-970D-B73D65E892E9Q30988544-1A4AD3EF-ED85-46E4-9009-1208BA996315Q33520381-15938BC6-12A8-46D8-B594-372293734FDDQ33935453-7B3381AC-B71F-4FE1-BAE5-C46CC0DE72D6Q33982978-C2B78BB8-10BC-4DB5-A4C7-E8EB7BDF43B7Q34001179-82F5470C-346A-410C-812E-2E85184E7257Q34041344-9EE6FC2E-D5A8-487F-BAED-974057805B38Q35091440-B3D52D03-62EE-45BC-82B5-BCFF42266C77Q35485418-2D8F1D88-955B-4A1F-A276-2CC1ED6DAB20Q35536511-ED87A670-1075-4612-ADCC-537F9877D52EQ35977922-07C09E92-261A-4F6B-A3C7-0FA75828CA24Q36470331-595D8CDC-9114-4F47-9153-1E2950F6CCCAQ36626892-80966046-6ED2-459C-97DD-8D3296F77333Q36963684-B5ECADCC-035A-4C77-92DE-374A62899FDDQ37061114-267B12FA-1284-4581-949B-4674BBEB5EC5Q37072090-11FE979A-8465-4466-87C9-B2329B67399AQ37394981-398A2D87-4121-4057-AAA6-7222949F7435Q37405207-DBEA4D84-8128-4F5A-AEA5-4A03D59D64B1Q37658774-0B2D7B57-9A2D-4151-B6E3-C16B4B7D2C61Q37773243-D0C282C6-4D54-42E1-AD5D-06D54FD7D2DEQ37846342-3FBA2FB5-2D99-41D7-ACA4-0B9A176AA306Q38150869-14EE61EB-74B4-4BB9-8AFA-81D35B7EFA36Q38729125-356D579F-F2B6-4CD0-9340-BFAA987C5F1EQ39038566-601E8B58-BC58-4BDC-B47B-E4238A2C6C03Q39172101-7D93DA66-09C8-48CB-ADB7-1E4717900243Q39923168-544F00F3-FD17-4993-89E0-8AEBE5C311AFQ42322097-D00F69B5-4FC3-4BEB-8CF9-8F4FECA01AB6Q50279494-E5179988-E82E-4101-9441-BA31CD2370F6Q51030489-9B15ACDA-9BD5-4DCD-8E62-5F7A82D9B19AQ53694846-D241A10F-D655-449D-84A4-583BA7BD131F
P2860
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@ast
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@en
type
label
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@ast
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@en
prefLabel
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@ast
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@en
P2860
P1476
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
@en
P2093
Menashe Bar-Eli
Vladislava O Melnikova
P2860
P304
P356
10.1111/J.1600-0749.2006.00331.X
P577
2006-10-01T00:00:00Z